Leerink Partnrs Weighs in on Atyr PHARMA FY2024 Earnings
Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...
Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated at Leerink Partners
Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...
Hosted on MSN3d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform Recommendation
Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Leerink Partners analyst Faisal Khurshid initiated coverage on aTyr Pharma Inc ATYR with an Outperform rating and announced a ...
aTyr Pharma initiated with an Outperform at Leerink
Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook
Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...
RBC Capital Keeps Their Buy Rating on aTyr Pharma (ATYR)
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...
Investing17d
aTyr Pharma CFO Broadfoot sells $4,740 in stock
SAN DIEGO—Jill Marie Broadfoot, the Chief Financial Officer of aTyr Pharma Inc (NASDAQ:ATYR), recently sold a portion of her holdings in the company. According to a recent SEC filing, Broadfoot sold 1 ...
Seeking Alpha18d
aTyr Pharma, Inc.
GLUEMonte Rosa Therapeutics, Inc. Monte Rosa Therapeutics, Inc. PRQRProQR Therapeutics N.V. ProQR Therapeutics N.V. ARQTArcutis Biotherapeutics, Inc. Arcutis ...